The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Therapeutic potential of adenosine A2A receptor antagonists in Parkinson's disease
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The functional anatomy of basal ganglia disorders
Albin, R. L., Young, A. B., & Penney, J. B. (1989) · Trends in Neurosciences · doi:10.1016/0166-2236(89)90074-x · Cited by 5,353
Fredholm, B. B., Bättig, K., Holmén, J., Nehlig, A., & Zvartau, E. E. (1999) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01396-6 · Cited by 2,624
Robinson, T. E., & Becker, J. B. (1986) · Brain Research Reviews · doi:10.1016/0165-0173(86)90002-0 · Cited by 1,796
Geyer, M. A., Krebs-Thomson, K., Braff, D. L., & Swerdlow, N. R. (2001) · Psychopharmacology · doi:10.1007/s002130100811 · Cited by 1,484
Mezey, É., Tóth, Z. E., Cortright, D. N., Arzubi, M. K., Krause, J. E., Elde, R., Guo, A., Blumberg, P. M., & Szallasi, A. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.7.3655 · Cited by 850
Association of coffee and caffeine intake with the risk of Parkinson disease
Ross, G. W. (2000) · JAMA · doi:10.1001/jama.283.20.2674 · Cited by 778
Prospective Study of Caffeine Consumption and Risk of Parkinson’s Disease in Men and Women
Ascherio, A., Zhang, S. M., Hernán, M. A., Kawachi, I., Colditz, G. A., Speizer, F. E., & Willett, W. C. (2001) · Annals of Neurology · doi:10.1002/ana.1052 · Cited by 677
Alternative excitotoxic hypotheses
Albin, R. L., & Greenamyre, J. T. (1992) · Neurology · doi:10.1212/wnl.42.4.733 · Cited by 574
Robinson, T. E., Jurson, P. A., Bennett, J. A., & Bentgen, K. M. (1988) · Brain Research · doi:10.1016/0006-8993(88)90549-5 · Cited by 463
Subthalamic GAD Gene Therapy in a Parkinson's Disease Rat Model
Luo, J., Kaplitt, M. G., Fitzsimons, H. L., Zuzga, D. S., Liu, Y., Oshinsky, M. L., & During, M. J. (2002) · Science · doi:10.1126/science.1074549 · Cited by 325
Cited by
Physiology and Pathophysiology of Purinergic Neurotransmission
Burnstock, G. (2007) · Physiological Reviews · doi:10.1152/physrev.00043.2006 · Cited by 1,585
Adenosine Receptors as Therapeutic Targets
Jacobson, K. A., & Gao, Z.-G. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1983 · Cited by 1,431
Epidemiology and etiology of Parkinson's disease: a review of the evidence
Wirdefeldt, K., Adami, H.-O., Cole, P., Trichopoulos, D., & Mandel, J. (2011) · European Journal of Epidemiology · doi:10.1007/s10654-011-9581-6 · Cited by 1,199
Multi-target-Directed Ligands To Combat Neurodegenerative Diseases
Cavalli, A., Bolognesi, M. L., Minarini, A., Rosini, M., Tumiatti, V., Recanatini, M., & Melchiorre, C. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm7009364 · Cited by 1,152
Pathophysiology and Therapeutic Potential of Purinergic Signaling
Burnstock, G. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.1.5 · Cited by 611
Targeting adenosine A2A receptors in Parkinson's disease
Schwarzschild, M. A., Agnati, L., Fuxe, K., Chen, J.-F., & Morelli, M. (2006) · Trends in Neurosciences · doi:10.1016/j.tins.2006.09.004 · Cited by 433
Self-citationAdenosine A2A receptor mediates microglial process retraction
Orr, A. G., Orr, A. L., Li, X.-J., Gross, R. E., & Traynelis, S. F. (2009) · Nature Neuroscience · doi:10.1038/nn.2341 · Cited by 362
The purines: Potent and versatile small molecule inhibitors and modulators of key biological targets
Legraverend, M., & Grierson, D. S. (2006) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2005.12.060 · Cited by 330
Serum Urate as a Predictor of Clinical and Radiographic Progression in Parkinson Disease
Schwarzschild, M. A. (2008) · Archives of Neurology · doi:10.1001/archneur.2008.65.6.nct70003 · Cited by 310
Self-citationNovel pharmacological targets for the treatment of Parkinson's disease
Schapira, A. H. V., Bezard, E., Brotchie, J., Calon, F., Collingridge, G. L., Ferger, B., Hengerer, B., Hirsch, E., Jenner, P., Novère, N. L., et al. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2087 · Cited by 298
Self-citationCaffeine for treatment of Parkinson disease: A randomized controlled trial
Postuma, R. B., Lang, A. E., Munhoz, R. P., Charland, K., Pelletier, A., Moscovich, M., Filla, L., Zanatta, D., Rios Romenets, S., Altman, R., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e318263570d · Cited by 298
Caffeine analogs: biomedical impact
Daly, J. W. (2007) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-007-7051-9 · Cited by 256
Caffeine and risk of Parkinson’s disease in a large cohort of men and women
Palacios, N., Gao, X., McCullough, M. L., Schwarzschild, M. A., Shah, R., Gapstur, S., & Ascherio, A. (2012) · Movement Disorders · doi:10.1002/mds.25076 · Cited by 185
Self-citationAdenosine receptor neurobiology: overview
Chen, J.-F., Lee, C.-F., & Chern, Y. (2014) · International review of neurobiology · doi:10.1016/b978-0-12-801022-8.00001-5 · Cited by 119
Chen, J.-F., & Schwarzschild, M. A. (2020) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2020.10.024 · Cited by 39
Self-citation
Metadata
- Authors
- Xu, K., Bastia, E., & Schwarzschild, M.
- Venue
- Pharmacology & Therapeutics
- Publisher
- Elsevier BV
- Published
- 2005-03
- Volume
- 105
- Issue
- 3
- Pages
- 267-310
- ISSN
- 0163-7258 (ISSN-L)
- OpenAlex
- W1982734210
- Cited by
- 244
- References
- 14
- FWCI
- 9.28
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.